// App-Quantinova.ai

549 : A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer patients (IRIS) Trial Results.

Researchers

Presenter

  • Carlo Palmieri

Principal Investigators

  • Robert C. Stein

  • Xinxue Liu

  • Emma Hudson

  • Sadie Reed

  • Hanna Nicholas

  • Sophie Barrett

  • Christopher Holcombe

  • Adrian Lim

  • Richard L Hayward

  • Sacha Jon Howell

  • Charles Coombes

Medical Centers

  • Institute of Translational Medicine, Liverpool, United Kingdom

  • University College London Hospitals NHS Trust, London, United Kingdom

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • Royal Liverpool University Hospital, Liverpool, United Kingdom

  • Imperial College NHS Trust Hospitals, Department of Radiology, London, United Kingdom

  • Edinburgh Royal Infirmary, Edinburgh, United Kingdom

  • University of Manchester, Manchester, United Kingdom

  • Imperial College, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Breast cancer

Biomarkers

  • N/A

Drug/Treatment

  • Irosustat

Outcome

  • N/A

Study Design

  • Pharmacodynamics

Phase

  • II

Study Id's

  • NCT01785992

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved